Evidence map›Paper›PMID 38919656›Full record

ArticleSouth Asian journal of cancer2024

Real-World Data on Treatment Outcome of ALK-Positive Non-Small Cell Lung Cancer from an Indian Multicentric Cancer Registry.

Lalatendu Moharana, Soumya Surath Panda, Suma Devaraj, Ghanashyam Biswas, Ganesh Chandra Subudhi, Prasant Kumar Parida, Sourav Kumar Mishra, Jogamaya Pattnaik, Sambit Mohanty, Sukanya Karunanidhi and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in South Asian journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Lalatendu MoharanaDepartment of Medical Oncology, The Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India.ORCID 0000-0002-5426-0356
Soumya Surath PandaDepartment of Medical Oncology, The Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India.
Suma DevarajDepartment of Medical Oncology, The Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India.
Ghanashyam BiswasDepartment of Medical Oncology, Sparsh Hospitals & Critical Care, Bhubaneswar, Odisha, India.
Ganesh Chandra SubudhiDepartment of Medical Oncology, Sparsh Hospitals & Critical Care, Bhubaneswar, Odisha, India.
Prasant Kumar ParidaDepartment of Medical Oncology, Acharya Harihar Post Graduate Institute of Cancer, Cuttack, Odisha, India.
Sourav Kumar MishraDepartment of Medical Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Jogamaya PattnaikDepartment of Medical Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Sambit MohantyDepartment of Pathology, Advanced Medicare & Research Institute, Bhubaneswar, Odisha, India.ORCID 0000-0001-5094-2424
Sukanya KarunanidhiDepartment of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India.
Sandhya Lakshmi SinguluriDepartment of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India.
S V SajuDepartment of Haematology and Medical Oncology, Meenakshi Mission Hospital and Research Centre, Madurai, Tamil Nadu, India.ORCID 0000-0003-0268-7937
Krishna Kumar RathnamDepartment of Haematology and Medical Oncology, Meenakshi Mission Hospital and Research Centre, Madurai, Tamil Nadu, India.
Amit SehrawatDepartment of Medical Oncology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.ORCID 0000-0001-7100-8999
Shikha MudgalDepartment of Medical Oncology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Sunu Lazar CyriacDepartment of Medical Oncology, Amala Institute of Medical Sciences, Thrissur, Kerala, India.
Ashwin PhilipsChristian Medical College Hospital, Ludhiana, Punjab, India.
Anil Kumar JoseDepartment of Medical Oncology, Amala Institute of Medical Sciences, Thrissur, Kerala, India.
Prasant GanesanDepartment of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India.ORCID 0000-0003-2762-6591

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lalatendu Moharana The Anaplastic lymphoma kinase inhibitors (ALKi) represent the standard of care for metastatic non-small cell lung cancer (NSCLC) patients with EML4-ALK rearrangements. Various ALKi agents are available; however, not all eligible patients receive treatment with them due to various reasons. Given the limited real-world data available in our country, we aimed to assess treatment outcomes through a multicenter collaboration. This retrospective, multi-institutional study was conducted under the Network of Oncology Clinical Trials India and included a total of 67 ALK-positive metastatic lung cancer patients from 10 institutes across India, with a median follow-up of 23 months. In the first line setting, the objective response rate (ORR) with ALKi was 63.6% (crizotinib: 60.7%, ceritinib: 70%, alectinib: 66.6%,

Indexed as

anaplastic lymphoma kinasenon-small cell lung cancerreal-world data

Identifiers

PMID38919656
PMCPMC11196141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.